Personne
Georgios Sflomos
Publications associées (15)
Is There a Special Role for Ovarian Hormones in the Pathogenesis of Lobular Carcinoma?
Cathrin Brisken, Georgios Sflomos
Lobular carcinoma represent the most common special histological subtype of breast cancer, with the majority classed as hormone receptor positive. Rates of invasive lobular carcinoma in postmenopausal women have been seen to increase globally, while other ...
Endocrine Soc2024Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma
Cathrin Brisken, Georgios Sflomos, Laura Battista
Simple Summary Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer and is often detected at an advanced stage. Up to 30% of ILC cases relapse and present a challenge for treatment. Unfortunately, there are few mod ...
MDPI2023Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence
Cathrin Brisken, Giovanna Ambrosini, Georgios Sflomos, Yueyun Zhang, Hazel Margaret Quinn, Kelly Spry Maggs, Patrik Aouad, Fabio De Martino, Céline Marie Victoria Stibolt
More than 70% of human breast cancers (BCs) are estrogen receptor α-positive (ER+). A clinical challenge of ER+ BC is that they can recur decades after initial treatments. Mechanisms governing latent disease remain elusive due to lack of adequate in vivo m ...
2022Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1
Cathrin Brisken, Giovanna Ambrosini, Georgios Sflomos, Ayyakkannu Ayyanan, Laura Battista, Philipp Bucher, Maryse Fiche, Valentina Scabia, Patrik Aouad, Fabio De Martino
Invasive lobular carcinoma (ILC) is the most frequent special histological subtype of breast cancer, typically characterized by loss of E‐cadherin. It has clinical features distinct from other estrogen receptor‐positive (ER+) breast cancers but the molecul ...
2021Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity
Cathrin Brisken, Georgios Sflomos, Laura Battista
Functional studies giving insight into the biology of circulating tumor cells (CTCs) remain scarce due to the low frequency ofCTCs and lack of appropriate models. Here, we describe the characterization of a novelCTC-derived breast cancer cell line, designa ...
WILEY2020A novel culture method that sustains ER alpha signaling in human breast cancer tissue microstructures
Cathrin Brisken, Georgios Sflomos
Background Estrogen receptor alpha (ER alpha) signaling is a defining and driving event in most breast cancers; ER alpha is detected in malignant epithelial cells of 75% of all breast cancers (classified as ER-positive breast cancer) and, in these cases, E ...
2020Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions
Cathrin Brisken, Georgios Sflomos, Ayyakkannu Ayyanan, Laura Battista, Maryse Fiche, Valentina Scabia, Patrik Aouad, Valérian Charles Robert Dormoy
Estrogen receptor α-positive (ER-positive) or 'luminal' breast cancers were notoriously difficult to establish as patient-derived xenografts (PDXs). We and others recently demonstrated that the microenvironment is critical for ER-positive tumor cells; when ...
2018Oestrogen receptor alpha AF-1 and AF-2 domains have cell population-specific functions in the mammary epithelium
Cathrin Brisken, Georgios Sflomos, Ayyakkannu Ayyanan, Valentina Scabia, Patrik Aouad, Dalya Ataca, Stéphanie Cagnet
Oestrogen receptor alpha (ER alpha) is a transcription factor with ligand-independent and ligand-dependent activation functions (AF)-1 and -2. Oestrogens control postnatal mammary gland development acting on a subset of mammary epithelial cells (MECs), ter ...
NATURE PUBLISHING GROUP2018A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response
Cathrin Brisken, Georgios Sflomos, Ayyakkannu Ayyanan, Laura Battista, Maryse Fiche, Valentina Scabia, Valérian Charles Robert Dormoy
Seventy-five percent of breast cancers are estrogen receptor α positive (ER(+)). Research on these tumors is hampered by lack of adequate in vivo models; cell line xenografts require non-physiological hormone supplements, and patient-derived xenografts (PD ...
Elsevier2016Patient-derived xenograft (PDX) models in basic and translational breast cancer research
Cathrin Brisken, Georgios Sflomos, Valentina Scabia
Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research. In breast cancer, to complement the now ...
Springer Verlag2016